Back to results
US 2020/0064347 A1Published application
Lung cancer markers and uses thereof
AssigneeCelera Corporation
InventorsCharles BIRSE, Steve RUBEN, Marcia LEWIS, Mehdi MESRI
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeCelera Corporation
InventorsCharles BIRSE, Steve RUBEN, Marcia LEWIS, Mehdi MESRI
Estimating the term…
Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness of a treatment or for selecting a treatment using LCM. Methods and compositions are further provided for modulating cell function using LCM. Also provided are compositions that modulate LCM (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate LCM, and agents identified by these screening methods.
A method of detecting lung cancer in an individual, the method comprising detecting the level of TFPI in a sample from said individual, wherein an elevated level of TFPI indicates that said individual has lung cancer.
A method of detecting lung cancer in an individual, the method comprising detecting the levels of a panel of markers selected from the group consisting of the panels provided in Table 5, wherein elevated levels of a plurality of said markers indicate that said individual has lung cancer.
6-17. (canceled)
20-21. (canceled)
23-27. (canceled)
A kit comprising at least one container and detection reagents for detecting a plurality of lung cancer markers comprising Cyfra, SLPI, TIMP1, SCC, TFPI, CEACAM5, MMP2, OPN, and MDK, wherein the detection reagents are stored in one or more of the containers.
39-43. (canceled)
The method of claim 17, wherein the method is carried out in conjunction with lung cancer treatment.
47-50. (canceled)
(canceled)
Dependencies are inferred from the claim text.